Relapsed or refractory multiple myeloma
Drug research and approvals for relapsed or refractory multiple myeloma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 99 studies of relapsed or refractory multiple myeloma are recruiting on ClinicalTrials.gov, Health Canada has authorized 66 drug trials for it since 2013, FDA has 17 approved and 0 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 99
- Trials authorized in Canada: 66
- FDA orphan approvals: 17
- EU medicines: 3
- SKCD in Early Relapsed/Refractory Multiple MyelomaNCT07931391 · Phase 2 · Beijing Chao Yang Hospital · starts Oct 31, 2026
- Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood CancersNCT07914556 · Phase 1 · Mabwell (Shanghai) Bioscience Co., Ltd. · starts Sep 16, 2026
- A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or…NCT07802717 · Phase 1 · Vyriad, Inc. · starts Sep 8, 2026
- Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple MyelomaNCT07772024 · Phase 3 · CellCentric Ltd. · starts Nov 18, 2026
- A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)NCT07771803 · Early Phase 1 · Roger Strair · starts Jun 30, 2025
- A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory…NCT07742215 · Phase 3 · Biocad · starts Jun 15, 2026
- A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple MyelomaNCT07735546 · Phase 1 · Umoja Biopharma · starts Nov 1, 2026
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus…NCT07728188 · Phase 3 · AbbVie · starts Oct 20, 2026
- Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple MyelomaNCT07725406 · Phase 1 · Weill Medical College of Cornell University · starts Nov 1, 2026
How its trials ended
3,427 ClinicalTrials.gov studies of multiple myeloma in general, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 969 whose ending is known, 35% met their primary endpoint, 4% missed it and 61% stopped early.
- Completed, result not reported1,18635%
- Ongoing95928%
- Met its primary endpoint33910%
- Status unknown3139%
- Stopped: other or unclear2718%
- Stopped: enrollment or feasibility1645%
- Stopped: sponsor or business decision852%
- Stopped: lack of efficacy431%
- Missed its primary endpoint361%
- Stopped: safety16<1%
- Stopped: funding15<1%
| Jul 17, 2026 | An open label phase 1b, multicenter study to evaluate the safety and efficacy of belantamab mafodotin plus cevostamab in participants with relapsed/refractory…Belantamab mafodotin / Cevostamab | Canadian Myeloma Research Group | Pending |
| Jun 1, 2026 | Safety and feasibility of teclistamab discontinuation in relapsed and refractory multiple myelomaTecvayli | Ciusss De L’est-De-L’île-De-Montréal – Hôpital Maisonneuve-Rosemont | Pending |
| Apr 2, 2026 | A phase 3 randomized study comparing JNJ-79635322 versus teclistamab in participants with relapsed or refractory multiple myeloma after 1 to 3 prior lines of…JNJ-79635322 / Tecvayli | Johnson & Johnson | Ongoing |
| Mar 5, 2026 | A phase 3 randomized study comparing JNJ-79635322 and an anti-bcmaxcd3 bispecific antibody in participants with relapsed or refractory multiple myeloma who…JNJ-79635322 / Teclistamab | Johnson & Johnson | Ongoing |
| Jan 13, 2026 | An open-label, randomized phase 3 study of linvoseltamab monotherapy and relapsed/refractory multiple myeloma standard of care combination regimens in patients…Lynozyfic (REGN5458) / Carfilzomib / Bortezomib / Dexamethasone | Regeneron | Pending |
| Dec 24, 2025 | A phase III open-label, randomised, multicentre study comparing AZD0120, a dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy directed…AZD0120 (GC012F) | AstraZeneca Pharmaceuticals | Ongoing |
| Jul 25, 2025 | A phase 1b/2a, multicenter, open-label study to determine the recommended dose and schedule, and evaluate the safety and preliminary efficacy of mezigdomide in…Mezigdomide (BMS-986348, CC-92480) / Elranatamab / Dexamethasone | Bristol-Myers Squibb | Ongoing |
| Mar 13, 2025 | A phase 1/2 study of etentamig in combination with a celmod agent for the treatment of patients with relapsed/refractory multiple myelomaEtentamig (ABBV-383) / Iberdomide | AbbVie | Ongoing |
| Oct 10, 2024 | A phase 3, randomized, open-label study to compare the efficacy and safety of anitocabtagene autoleucel versus standard of care therapy in participants with…Anitocabtagene autoleucel | Kitepharma Inc | Ongoing |
| Sep 11, 2024 | A first-in-human, open-label, phase 1 study to evaluate the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of subcutaneous SAR446523, an…SAR446523 | Sanofi-Aventis Canada Inc | Ongoing |
| Mar 5, 2026 | TecvayliTreatment of adult patients with relapsed or refractory multiple myeloma in combination with daratumumab hyaluronidase-fihj in patients who… | Janssen Research & Development, LLC | Approved |
| Oct 23, 2025 | BlenrepIn combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have… | GlaxoSmithKline Intellectual Property Development Ltd. | Approved |
| Jul 2, 2025 | LynozyficTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including… | Regeneron Pharmaceuticals, Inc. | Approved |
| Apr 5, 2024 | CarvyktiTreatment of adult patients with relapsed or refractory multiple myeloma, who have received at least 1 prior line of therapy, including a… | Janssen Research & Development, LLC | Approved |
| Apr 4, 2024 | AbecmaTreatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an… | Celgene Corporation, a Bristol-Myers Squibb Company | Approved |
| Aug 14, 2023 | ElrexfioTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including… | Pfizer Inc. | Approved |
| Aug 9, 2023 | TalveyTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including… | Janssen Biotech, inc. | Approved |
| Oct 25, 2022 | TecvayliTreatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including… | Janssen Research & Development, LLC | Approved |
| Jun 30, 2022 | KyprolisTreatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination… | Onyx Therapeutics, Inc. | Approved |
| Feb 28, 2022 | CarvyktiTreatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome… | Janssen Research & Development, LLC | Approved |
| Nov 30, 2021 | KyprolisTreatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination… | Onyx Therapeutics, Inc. | Approved |
| Mar 31, 2021 | SarclisaIn combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who… | Sanofi-Aventis U.S. LLC | Approved |
| Mar 26, 2021 | AbecmaTreatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an… | Celgene Corporation, a Bristol-Myers Squibb Company | Approved |
| Feb 26, 2021 | PepaxtoTreatment, in combination with dexamethasone, of adult patients with relapsed or refractory multiple myeloma who have received at least… | Oncopeptides AB | Approved |
| Aug 20, 2020 | KyprolisTreatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination… | Onyx Therapeutics, Inc. | Approved |
| Jul 23, 2025 | BlenrepBelantamab mafodotin | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| Apr 23, 2025 | LynozyficLinvoseltamab | Regeneron Ireland Designated Activity Company (DAC) | EMA ↗ |
| Aug 23, 2022 | TecvayliTeclistamab | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA